|
2/2 The Alabama State University/UAB Comprehensive Cancer Center Partnership
|
5P20CA192976-04
|
$144,556
|
MISHRA, MANOJ
|
ALABAMA STATE UNIVERSITY
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Optimization of Non-Ablative Focused Ultrasound Therapy for Tumor Immunity
|
5F30CA200411-04
|
$49,044
|
SKALINA, KARIN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Contributions of sympathetic signals to prostate cancer progression.
|
5F30CA203446-02
|
$49,044
|
ZAHALKA, ALI
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-02
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
A NOVEL SMALL MOLECULE CX3CR1 ANTAGONIST HALTS METASTASIS
|
2R44CA183362-02A1
|
$822,075
|
SALVINO, JOSEPH
|
ALLIANCE DISCOVERY, INC.
|
|
Preparation of site-specific antibody-drug conjugates by proximity-based sortase ligation
|
1R41CA221374-01
|
$224,996
|
TSOURKAS, ANDREW
|
ALPHATHERA, INC.
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
5R44CA203199-02
|
$402,226
|
TAYLOR, IAN
|
ARVINAS, INC.
|
|
ARF1 signaling in prostate cancer
|
1R56CA204315-01A1
|
$243,960
|
WU, GUANGYU
|
AUGUSTA UNIVERSITY
|
|
Functional Investigation of the Mitochondrial Pyruvate Carrier in Prostate Cancer
|
5F30CA196108-03
|
$38,455
|
BADER, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Germ Cell Gene TDRD1 As A Novel Prostate Cancer Biomarker
|
1R01CA211861-01A1
|
$362,569
|
HE, BIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Mitochondrial Heterogeneity in Pyruvate Flux in Prostate Cancer Progression
|
5R21CA205257-02
|
$172,369
|
MCGUIRE, SEAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Notch Signaling in Prostate Homeostasis and Carcinogenesis
|
5R01CA190378-03
|
$362,569
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reprogramming of Prostate Stromal Cells by Prostate Inflammation
|
5R21CA196570-02
|
$185,247
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Androgen Signaling in prostate cancer progression and CRPC development
|
5R01CA070297-19
|
$1
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A New Mechanism for Castration Resistant Prostate Cancer
|
5R01CA166894-05
|
$1
|
SUN, ZIJIE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Androgen Receptor Action in Castration Resistant Prostate Cancer
|
5P01CA163227-05
|
$2,045,478
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
5R01CA168393-04
|
$361,050
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Tumor Suppressive Pathways for Cancer Therapy
|
5R35CA197529-03
|
$1,044,000
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
5R01CA200573-02
|
$395,738
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Elucidating a Novel Mechanism for SPOP in Suppressing Prostate Tumorigenesis
|
1K99CA212292-01
|
$168,804
|
ZHANG, JINFANG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
RASL-Seq Expression Profiling of FFPE Tissues
|
5R33CA183688-03
|
$332,225
|
YEAKLEY, JOANNE
|
BIOSPYDER TECHNOLOGIES, INC.
|
|
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor
|
1R01CA211646-01
|
$415,154
|
ZETTER, BRUCE
|
BOSTON CHILDREN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-04S1
|
$2,088,480
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-04
|
$11,145,123
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Co-targeting oncogenic pathways in advanced prostate cancer
|
5R01CA198097-02
|
$381,212
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Quantitative Image Informatics for Cancer Research (QIICR)
|
3U24CA180918-05S1
|
$254,713
|
KIKINIS, RON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Quantitative Image Informatics for Cancer Research (QIICR)
|
5U24CA180918-05
|
$668,865
|
KIKINIS, RON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Impact of aging on prostate cancer with TMPRSS2-ETS gene fusion
|
5UH2CA213392-02
|
$44,999
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Advancement and Validation of Prostate Diffusion and Spectroscopic MRI
|
5R01CA160902-06
|
$220,860
|
MAIER, STEPHAN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
The VITamin D and OmegA-3 TriaL (VITAL)
|
5R01CA138962-09
|
$3,203,095
|
MANSON, JOANN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics
|
2R01CA105304-11A1
|
$260,847
|
SADAR, MARIANNE
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Impact of social and built environments on health-related quality of life for cancer survivors
|
5R03CA202192-02
|
$74,500
|
SHARIFF-MARCO, SALMA
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S1
|
$118,875
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S2
|
$60,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S3
|
$200,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S4
|
$145,821
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-27
|
$4,895,515
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Nuclear Factor I/B Action in Castrate Resistant Prostate Cancer
|
4R00CA197315-04
|
$249,000
|
GRABOWSKA, MAGDALENA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
MR Fingerprinting and Computerized Decision Support for Prostate Cancer
|
1R01CA208236-01A1
|
$554,035
|
GULANI, VIKAS
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeted MRI contrast agents for differential diagnosis of prostate cancer
|
1R01CA211762-01A1
|
$423,352
|
LU, ZHENG-RONG
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-04S1
|
$76,498
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-04
|
$1,188,450
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|